Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Views for Sarepta on Prosensa's IPO

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Sarepta Therapeutics (NASDAQ: SRPT  )  won't be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer.  Its one potential challenger on the scene, Prosensa, recently announced plans to move forward with an initial public offering. Here are three views on what a Prosensa IPO could mean for Sarepta.

Prosensa's IPO won't have much impact on the progress of its DMD drug, drisapersen. The Dutch biotech didn't need to raise money to keep development going for the drug. GlaxoSmithKline (NYSE: GSK  ) obtained rights to drisapersen back in 2009 and funds the development effort. Similarly, Prosensa doesn't really need to worry about footing the bill for commercialization of the drug, assuming it ultimately gains regulatory approval. Glaxo will also handle the finances there.

A publicly traded Prosensa doesn't threaten Sarepta any more than it would as a privately held company. However, it could possibly have a negative impact on Sarepta's shares. How? Investors could decide to hedge their bets by buying Prosensa shares (when available) rather than buying more Sarepta stock. This would lessen demand for Sarepta to some extent. Weaker demand would serve as a drag on the stock, keeping it from rising as high as it could reach.

On the other hand, a couple of aspects of Prosensa going public could boost Sarepta's shares. The fact that Glaxo didn't buy Prosensa is interesting, to say the least. Some investors could read between the lines and suspect that the big pharmaceutical company knows something that makes Prosensa less attractive as an acquisition target. If this proves to be the case, Sarepta wins.

Prosensa's SEC filing also raises questions yet again about the safety profile for drisapersen. There have been serious concerns in the past about the protein in the urine of patients taking the drug. In its F-1 document filed in preparation for the IPO, Prosensa mentioned this along with several other adverse effects. The reminder about possible safety issues with drisapersen could make eteplirsen look that much better in the eyes of investors. Of course, the better eteplirsen looks, the better Sarepta looks as an investment alternative.

The third view is that Prosensa's planned IPO doesn't matter much at all for Sarepta. After all, Glaxo owns the rights to drisapersen. Whether Prosensa is publicly traded or owned by aliens from another planet shouldn't really have bearing on what happens with drisapersen. 

Another possible twist to this view is that we don't have to necessarily rule out negative or positive effects on Sarepta's stock from the Prosensa IPO. However, under this twist, whatever effects occur will cancel each other out.

Foolish take
Count me in the neutral corner on this one. Prosensa filed its F-1 on May 28. While Sarepta's shares bounced up and down some since then, they're close to the same price level where they were before the IPO announcement. 

What really matters for Sarepta right now is how quickly eteplirsen can get to market. Whether the company can gain accelerated approval makes nearly everything else irrelevant in the near term. I'm in the undecided corner there, because I think it could go either way.

I'm not neutral or undecided on Sarepta over the long run, though. My take is that the company will gain approval for eteplirsen (sooner or later). The stock has more room to run. If you're an investor, room to run is always the room with best view.

It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long-term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2496188, ~/Articles/ArticleHandler.aspx, 9/27/2016 4:50:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
SRPT $59.10 Down -0.56 -0.94%
Sarepta Therapeuti… CAPS Rating: **
GSK $43.32 Up +0.36 +0.84%
GlaxoSmithKline CAPS Rating: ***